Procalcitonin in Hepatocellular Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01518829
Recruitment Status : Completed
First Posted : January 26, 2012
Last Update Posted : October 1, 2013
Information provided by (Responsible Party):
Iman Fawzy Montasser, Ain Shams University

Brief Summary:
the value of serum procalcitonin in differentiation between bacterial infection and non infectious inflammation in febrile HCC patients following locoeregional treatment for HCC.

Condition or disease
Hepatocellular Carcinoma

Study Type : Observational
Actual Enrollment : 42 participants
Observational Model: Case Control
Time Perspective: Prospective
Official Title: Role of Procalcitonin in Differantiation Between Bacerial Infection and Non Infectious Inflammation in Febrile Hepatocellular Carcinoma Patients After Locoregional Treatment
Study Start Date : April 2012
Actual Primary Completion Date : December 2012
Actual Study Completion Date : January 2013

Patients with hepatocellular carcinoma
Patients with hepatocellular carcinoma who will undergo locoregional therapy
patients with chronic liver disease
patients with chronic liver disease, as a control group

Primary Outcome Measures :
  1. Differantiate between post- embolization syndrom and sepsis following locoregional treatment for hepatocellular carcinoma [ Time Frame: 6months ]

Biospecimen Retention:   Samples Without DNA

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
inpatients in tropical medicine department and hepatocellular carcinoma out patient clinic ain shams university

Inclusion Criteria:

  1. - Hepatocellular carcinoma patients who will undergo TACE and/or radio-frequency.
  2. - Fever more than 38C after 48 hours post intervention.

Exclusion Criteria:

  1. HCC Patients who does not develop fever after intervention.
  2. Proven infection elsewhere (e.g. UTI, chest infection..)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01518829

Tropical medicine department and hepatocellular carcinoma clinic
Cairo, Egypt
Sponsors and Collaborators
Ain Shams University
Principal Investigator: Hisham K Dabbous, professor Tropical medicine department

Responsible Party: Iman Fawzy Montasser, Lecturer of Tropical medicine ,Faculty of Medicine,Ain Shams university, Ain Shams University Identifier: NCT01518829     History of Changes
Other Study ID Numbers: HCC and Procalcitonin
First Posted: January 26, 2012    Key Record Dates
Last Update Posted: October 1, 2013
Last Verified: September 2013

Keywords provided by Iman Fawzy Montasser, Ain Shams University:
hepatocellular carcinom
postablation syndrom

Additional relevant MeSH terms:
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases
Bone Density Conservation Agents
Physiological Effects of Drugs